newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Grants of Inducement Awards

  • Crescent Biopharma's Compensation Committee approved grants of 81,525 stock options to six non-executive employees on October 5, 2026.
  • The awards were issued under the 2025 Employment Inducement Incentive Award Plan to facilitate employee hiring as required by Nasdaq Listing Rule 5635(c)(4).
  • Each option has a 10-year term & an exercise price of $13.94, matching the closing share price on the grant date.
  • Vesting schedules include one-fourth of shares exercisable after the first anniversary of the start date, with one-fortieth-eighth vesting monthly thereafter, contingent on continuous service.
  • Crescent Biopharma is a clinical-stage oncology company focused on advancing therapies including a PD-1 x VEGF bispecific antibody & novel antibody-drug conjugates.